Navigation Links
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
Date:5/31/2008

re than 100 million American adults have elevated total cholesterol. Of the 30 million Americans currently on lipid-altering therapies, the majority are not reaching treatment goals. Treatment guidelines endorsed by the National Cholesterol Education Panel, the American College of Cardiology and the AHA have called for more aggressive management of lipids, including a lower LDL goal for many patients, as well as more aggressive management of HDL and triglycerides.

About the Study

The efficacy and safety of TriLipix in combination with rosuvastatin was evaluated in a randomized, double-blind, controlled, 12-week, Phase III study of 1,445 patients with mixed dyslipidemia. Patients included in the study had multiple lipid problems, with an LDL greater than or equal to 130 mg/dL, triglycerides greater than or equal to 150 mg/dL and HDL less than 40 mg/dL for men and less than 50 mg/dL for women.

Patients were randomized to receive TriLipix (135mg) combined with either 10mg or 20mg of rosuvastatin, TriLipix monotherapy (135mg) or rosuvastatin monotherapy (10mg, 20mg or 40mg). The 40mg rosuvastatin monotherapy arm was included in the study to assess safety and adverse events, but was not included in the statistical analysis.

The primary efficacy comparisons were mean percent change in HDL and triglycerides in the combination compared to rosuvastatin monotherapy, and mean percent change in LDL in the combination compared to TriLipix monotherapy. The study met all of its primary endpoints. Patients treated with the combination of TriLipix 135mg and rosuvastatin 10mg had an increase in HDL of 20.3 percent and decrease in triglycerides of 47.1 percent compared to an HDL increase of 8.5 percent and triglyceride decrease of 24.4 percent with rosuvastatin 10mg alone. LDL decreased 37.2 percent with the combination compared to 6.5 percent with TriLipix 135mg monotherapy.

Patients treated with the combination of TriLipix 135mg and rosuvastatin 20
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
(Date:12/24/2014)... N.J. and FARMINGTON, Conn. ... Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company ... of diseases with significant unmet medical need and ... on a private placement of 2,050,000 shares of ... purchase 24,949,325 shares of its common stock.  Funds ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... 4, 2011 Bioness Inc. today ... of the FASTEST study to further examine the impact of ... drop as a result of stroke. The FASTEST study aims ... System over standard therapy with an ankle-foot orthosis (AFO), and ...
... Inc. (NASDAQ: NBIX ) today announced that it ... for elagolix and next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. ... with the FDA, the outcome of which generated a $20 ... event brings the total milestones achieved by the Company in ...
Cached Medicine Technology:Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study 2Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement 2
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... current state of the global Sterilizers industry with a ... statistics on the market status of the Sterilizers manufacturers ... for companies and individuals interested in the industry. This ... its definition, applications and manufacturing technology. In this part, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... Patients with post-traumatic stress disorder show reduced pain sensitivity, ... processing in the brain, according to a report. ... may occur in individuals exposed to a traumatic event. ... event, and avoidance of stimuli related to the event, ...
... major Ranbaxy Laboratories Limited has received the approval from ... and market generic hypertension drug Atenolol in the country. ... 25 mg, 50 mg, and 100 mg dosage manufactured ... first quarter of 2007, the company said in a ...
... revolution in the lives of lepers in China.// ,Fu ... one day to live in a leper colony and offer ... a huge difference to hundreds of lepers in south China. ... Tanshan Leper Rehabilitation Village in Gaoming district. She has devoted ...
... polio is far from over in Bihar, which recorded 51 new ... polio cases surfaced in the state even though millions were spent ... ,Unofficial sources put the figure of polio cases at over ... the viral were detected in Kishanganj, Purnea, East Champaran and Sitamarhi ...
... Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives ... mineral supplement while pregnant may be less likely than women ... weighing less than 2,500 grams, and their newborns may be ... of life. ,Low birth weight, or a weight ...
... belief that cutting down on calories could help in ... meaning.// Researchers from University of Alabama at Birmingham suggest ... cancer is the body composition (being lean or obese) ... consumed, which mounts the risk of cancer., ,During ...
Cached Medicine News:Health News:Patients With PTSD Experience Less Pain Sensitivity 2Health News:A ‘Good Samaritan’ to the Aid of Lepe 2Health News:A ‘Good Samaritan’ to the Aid of Lepe 3Health News:Multivitamins Can Reduce Risk Of Low Birth Weight 2
... Graft Chambers have been designed to work ... System and are available exclusively through LifeNet. ... with a mixture of allograft cancellous chips ... allograft tissue within the chamber possesses both ...
With the Leica D2D V3 video and photography system you can produce fantastic digital videos and pictures with the highest resolution....
... connection of two state-of-the-art progressive scan digital ... beamsplitter on your microscope. The c-mount digital ... firewire cards and receive their power directly ... optical visualization without interference or compromise. The ...
... The Sony DXC-C33 camera is a high resolution ... TV lines resolution and also DV output capability. ... C-mount that will fit on almost any microscope. ... size is an issue. The camera control unit ...
Medicine Products: